Deep learning—a form of artificial intelligence capable of improving itself with limited user input—has radically reshaped the landscape of biomedical research since its emergence in the early 2010s.

Deep Genomics is taking two emerging technologies—which in recent years have captured the public’s attention for different reasons—and is finding they can work great together. The company has put ...

TORONTO--(BUSINESS WIRE)--Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today the release of the manuscript, “An RNA ...

Artificial intelligence (AI) machine learning is rapidly emerging as a powerful tool in the quest for novel diagnostics, therapies, and treatment for complex diseases such as cancer. Increasingly, ...

TORONTO--(BUSINESS WIRE)--Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today that its founder and Chief Innovation ...

Frey is founder and chief innovation officer of Deep Genomics. In a time of relentless AI hype and mounting global economic uncertainty, the real winners will be those who think long-term. One of the ...